Stockscreener 앱 받기
17.63
0.63%
0.11
시간 외 거래:
17.74
0.11
+0.62%
전일 마감가:
$17.52
열려 있는:
$17.88
하루 거래량:
3.66M
Relative Volume:
1.73
시가총액:
$1.78B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-9.7403
EPS:
-1.81
순현금흐름:
$-153.40M
1주 성능:
-1.29%
1개월 성능:
-16.72%
6개월 성능:
-45.59%
1년 성능:
-24.53%
1일 변동 폭
$17.03
$18.23
1주일 범위
$16.65
$18.23
52주 변동 폭
$13.53
$35.25
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
17.63 | 1.77B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease - Pharmacy Times
Beam Therapeutics Stock Surges After FDA Grants RMAT Designation - MSN
Beam Therapeutics stock surges after FDA grants RMAT designation By Investing.com - Investing.com Canada
Beam Therapeutics stock surges after FDA grants RMAT designation - Investing.com
Beam Therapeutics Gets FDA Regenerative Medicine Status for BEAM-101 to Treat Sickle Cell Disease - MarketScreener
Beam gains FDA Regenerative Medicine Advanced Therapy status for sickle cell treatment - Seeking Alpha
Beam Therapeutics' Sickle Cell Treatment Gets FDA's Generative Medicine Advanced Therapy Designation - MarketWatch
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy By Investing.com - Investing.com Australia
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam's Sickle Cell Gene Therapy Gets FDA Speed Boost After Strong Trial Data in 30 Patients - Stock Titan
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance
Will Beam Therapeutics Inc. benefit from government policyROI-Driven Capital Plans - thegnnews.com
Beam Therapeutics (NASDAQ:BEAM) Price Target Cut to $21.00 by Analysts at Barclays - MarketBeat
Beam Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsFree Access to Community - beatles.ru
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark - MSN
Beam Therapeutics: Analyst Maintains Buy Rating Amid Promising Trials and Solid Financials - AInvest
Beam Therapeutics: A Promising Genetic Medicine Player with Multiple Upcoming Catalysts - AInvest
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - 富途牛牛
Leerink Partners Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $42 - 富途牛牛
Beam Therapeutics Receives Buy Rating from Leerink Partners with $42 Price Target - AInvest
Beam Therapeutics Reports Q2 2025 Financials, Promising BEAM-302 Results in AATD Trial and Completion of BEACON Trial for Sickle Cell Disease. - AInvest
Beam Therapeutics Reports Q2 Revenue Below Consensus, Highlights Clinical Progress in Priority Programs - AInvest
Beam Therapeutics: A Narrower Loss in Q2 2025—Sign of a Sustainable Turnaround or a Temporary Bounce? - AInvest
Beam Therapeutics 2025 Q2 Earnings Net Loss Widen Despite EPS Improvement - AInvest
BEAM: Barclays Lowers Price Target with Equal-Weight Rating | BE - GuruFocus
Positive Developments and Financial Strength Bolster Beam Therapeutics’ Buy Rating - TipRanks
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates - MSN
Beam Therapeutics Reports Q2 2025 Financial Results - TipRanks
Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus
Evaluating the High-Growth Potential of Biopharma Innovators in 2025: A Deep Dive into Day One, Beam Therapeutics, and Syndax Pharmaceuticals - AInvest
Beam Therapeutics shares fall 1.59% intraday after Q2 net loss widens more than expected. - AInvest
Clear Street reiterates Buy rating on Beam Therapeutics stock at $34 - Investing.com
Beam Therapeutics Q2 Net Loss Narrows, Revenue Falls - MarketScreener
Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Beam Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Beam (BEAM) Advances in AATD Treatment with Promising BEAM-302 T - GuruFocus
BEAM Reports Q2 Revenue Below Consensus and Highlights Significa - GuruFocus
Beam Therapeutics Inc Reports Q2 2025 EPS of -$1.00, Beating Est - GuruFocus
Beam Therapeutics Q2 net loss widens more than expected - MarketScreener
Beam Therapeutics Inc. SEC 10-Q Report - TradingView
Earnings Flash (BEAM) Beam Therapeutics Posts Q2 $1 Loss, vs. FactSet Est of $1.11 Loss - MarketScreener
Beam Therapeutics Reports Positive Clinical Updates for BEAM-302 and BEAM-101, Financial Results for Q2 2025 - Quiver Quantitative
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) - The Manila Times
Beam Therapeutics Reports Second Quarter 2025 Financial - GlobeNewswire
Beam Therapeutics' AATD Treatment Achieves Major Clinical Milestone: 17 Patients Show Durable Disease Correction - Stock Titan
Beam Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus
When is Beam Therapeutics Inc. stock expected to show significant growthBuild a diversified portfolio for steady growth - Jammu Links News
What makes Beam Therapeutics Inc. stock price move sharplyCapitalize on momentum-driven stocks - Jammu Links News
How many analysts rate Beam Therapeutics Inc. as a “Buy”Unlock real-time stock alerts for quick profits - Jammu Links News
Is it the right time to buy Beam Therapeutics Inc. stockAchieve rapid portfolio growth with expert help - Jammu Links News
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
1.56%
자본화:
|
볼륨(24시간):